S&P 500   4,344.38 (+0.33%)
DOW   34,113.12 (+0.13%)
QQQ   359.36 (+0.42%)
AAPL   174.88 (+0.55%)
MSFT   319.04 (-0.15%)
META   302.41 (+2.26%)
GOOGL   131.24 (+0.61%)
AMZN   130.43 (+0.85%)
TSLA   254.13 (-0.61%)
NVDA   414.24 (+0.99%)
NIO   8.61 (+1.89%)
BABA   88.67 (+5.42%)
AMD   97.19 (+1.12%)
T   15.15 (-1.05%)
F   12.60 (+3.28%)
MU   68.81 (+1.34%)
CGC   0.80 (+4.91%)
GE   112.97 (-0.02%)
DIS   82.41 (-0.39%)
AMC   7.72 (+0.26%)
PFE   32.56 (-0.88%)
PYPL   58.56 (-0.10%)
NFLX   382.91 (-0.32%)
S&P 500   4,344.38 (+0.33%)
DOW   34,113.12 (+0.13%)
QQQ   359.36 (+0.42%)
AAPL   174.88 (+0.55%)
MSFT   319.04 (-0.15%)
META   302.41 (+2.26%)
GOOGL   131.24 (+0.61%)
AMZN   130.43 (+0.85%)
TSLA   254.13 (-0.61%)
NVDA   414.24 (+0.99%)
NIO   8.61 (+1.89%)
BABA   88.67 (+5.42%)
AMD   97.19 (+1.12%)
T   15.15 (-1.05%)
F   12.60 (+3.28%)
MU   68.81 (+1.34%)
CGC   0.80 (+4.91%)
GE   112.97 (-0.02%)
DIS   82.41 (-0.39%)
AMC   7.72 (+0.26%)
PFE   32.56 (-0.88%)
PYPL   58.56 (-0.10%)
NFLX   382.91 (-0.32%)
S&P 500   4,344.38 (+0.33%)
DOW   34,113.12 (+0.13%)
QQQ   359.36 (+0.42%)
AAPL   174.88 (+0.55%)
MSFT   319.04 (-0.15%)
META   302.41 (+2.26%)
GOOGL   131.24 (+0.61%)
AMZN   130.43 (+0.85%)
TSLA   254.13 (-0.61%)
NVDA   414.24 (+0.99%)
NIO   8.61 (+1.89%)
BABA   88.67 (+5.42%)
AMD   97.19 (+1.12%)
T   15.15 (-1.05%)
F   12.60 (+3.28%)
MU   68.81 (+1.34%)
CGC   0.80 (+4.91%)
GE   112.97 (-0.02%)
DIS   82.41 (-0.39%)
AMC   7.72 (+0.26%)
PFE   32.56 (-0.88%)
PYPL   58.56 (-0.10%)
NFLX   382.91 (-0.32%)
S&P 500   4,344.38 (+0.33%)
DOW   34,113.12 (+0.13%)
QQQ   359.36 (+0.42%)
AAPL   174.88 (+0.55%)
MSFT   319.04 (-0.15%)
META   302.41 (+2.26%)
GOOGL   131.24 (+0.61%)
AMZN   130.43 (+0.85%)
TSLA   254.13 (-0.61%)
NVDA   414.24 (+0.99%)
NIO   8.61 (+1.89%)
BABA   88.67 (+5.42%)
AMD   97.19 (+1.12%)
T   15.15 (-1.05%)
F   12.60 (+3.28%)
MU   68.81 (+1.34%)
CGC   0.80 (+4.91%)
GE   112.97 (-0.02%)
DIS   82.41 (-0.39%)
AMC   7.72 (+0.26%)
PFE   32.56 (-0.88%)
PYPL   58.56 (-0.10%)
NFLX   382.91 (-0.32%)
NASDAQ:IVVD

Invivyd (IVVD) Stock Forecast, Price & News

$1.64
-0.02 (-1.20%)
(As of 10:21 AM ET)
Compare
Today's Range
$1.60
$1.66
50-Day Range
$1.35
$1.89
52-Week Range
$0.98
$4.09
Volume
7,684 shs
Average Volume
280,566 shs
Market Capitalization
$180.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Invivyd MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
82.9% Upside
$3.00 Price Target
Short Interest
Healthy
4.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.87) to ($0.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

619th out of 964 stocks

Biological Products, Except Diagnostic Industry

95th out of 160 stocks


IVVD stock logo

About Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

IVVD Price History

IVVD Stock News Headlines

Invivyd to Participate in Upcoming Investor Conferences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
Invivyd gets new finance chief
Invivyd Appoints William Duke As New CFO
Invivyd Appoints William Duke as Chief Financial Officer
Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
H.C. Wainwright Sticks to Its Buy Rating for Invivyd (IVVD)
What 4 Analyst Ratings Have To Say About Invivyd
Invivyd: Q1 Earnings Insights
4IVVD : Earnings Preview: Invivyd
See More Headlines
Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

IVVD Company Calendar

Last Earnings
8/10/2023
Today
9/21/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IVVD
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+80.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-241,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.27 per share

Miscellaneous

Free Float
88,793,000
Market Cap
$182.19 million
Optionable
Optionable
Beta
-0.12
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. David Hering M.B.A. (Age 47)
    CEO & Director
    Comp: $932.5k
  • Ms. Jill Andersen J.D. (Age 50)
    Chief Legal Officer & Corp. Sec.
    Comp: $619.33k
  • Mr. William E. Duke Jr. (Age 51)
    M.B.A., Chief Financial Officer
  • Mr. Jeremy Gowler (Age 46)
    Chief Operating Officer & Chief Commercial Officer
  • Ms. Stacy Price M.S. (Age 54)
    Chief Technology & Manufacturing Officer
  • Dr. Robert D. Allen Ph.D.
    Chief Scientific Officer
  • Ms. Julie Green M.B.A.
    Sr. VP of HR
  • Dr. Peter C. Schmidt M.D. (Age 42)
    M.S., M.Sc., Chief Medical Officer
  • Ms. Heidi Spurling M.S.
    VP of Strategy & Operations and Chief of Staff to the CEO













IVVD Stock - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IVVD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IVVD, but not buy additional shares or sell existing shares.
View IVVD analyst ratings
or view top-rated stocks.

What is Invivyd's stock price forecast for 2023?

2 Wall Street analysts have issued twelve-month target prices for Invivyd's stock. Their IVVD share price forecasts range from $1.00 to $5.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 80.7% from the stock's current price.
View analysts price targets for IVVD
or view top-rated stocks among Wall Street analysts.

How have IVVD shares performed in 2023?

Invivyd's stock was trading at $1.50 at the start of the year. Since then, IVVD shares have increased by 10.7% and is now trading at $1.66.
View the best growth stocks for 2023 here
.

Are investors shorting Invivyd?

Invivyd saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,940,000 shares, a drop of 18.1% from the August 15th total of 2,370,000 shares. Based on an average daily volume of 387,900 shares, the short-interest ratio is presently 5.0 days. Currently, 4.9% of the shares of the stock are short sold.
View Invivyd's Short Interest
.

When is Invivyd's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IVVD earnings forecast
.

How were Invivyd's earnings last quarter?

Invivyd, Inc. (NASDAQ:IVVD) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.06.

What ETF holds Invivyd's stock ?

ETFMG Treatments Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio.

What is Invivyd's stock symbol?

Invivyd trades on the NASDAQ under the ticker symbol "IVVD."

Who are Invivyd's major shareholders?

Invivyd's stock is owned by a variety of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (3.64%), Citigroup Inc. (2.13%), BlackRock Inc. (1.20%), Geode Capital Management LLC (0.47%), Charles Schwab Investment Management Inc. (0.26%) and RBF Capital LLC (0.19%).

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invivyd's stock price today?

One share of IVVD stock can currently be purchased for approximately $1.66.

How much money does Invivyd make?

Invivyd (NASDAQ:IVVD) has a market capitalization of $182.19 million. The company earns $-241,320,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

How can I contact Invivyd?

Invivyd's mailing address is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. The official website for the company is adagiotx.com. The company can be reached via phone at 781-819-0080 or via email at investors@adagiotx.com.

This page (NASDAQ:IVVD) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -